Roche (RHHBY.US) Launches Brand Battle Ahead of New Drug Approval! Wilserdly Targets the US$10 Billion Breast Cancer Treatment Market

Roche (RHHBY.US) Plans to Name Its New Breast Cancer Oral Drug Wilserdly, Registering the Name in Multiple Jurisdictions. According to the United States Patent and Trademark Office (USPTO), Roche's U.S. subsidiary Genentech filed a trademark application on October 27 to register the name in uppercase letters, along with a floral design mark. Roche has also filed applications for the same brand name with multiple regulatory authorities worldwide, including the European Union Intellectual Property Office. People familiar with the matter who declined to be named said the brand name Roche selected for its giredestrant therapy contains the abbreviation "SERD," which stands for Selective Estrogen Receptor Degraders, a class of drugs that destroy the receptors breast cancer cells rely on to grow. Naming a new drug is a complex task. Pharmaceutical companies typically hire firms that specialize in drug naming. Brand names cannot be too similar to other drug names and must be easy for consumers in different language environments to pronounce. Drug names cannot over-promote the product or imply that the drug has overly remarkable efficacy, but ideally they need to resonate with consumers and the doctors who prescribe them. Ultimately, drug names still require regulatory approval. The name reflects Roche's ambition to put its stamp on an emerging class of drugs that could reshape treatment for the most common type of breast cancer. The success of Wilserdly is crucial for the Swiss drugmaker. Analysts believe the drug has the potential to become a blockbuster with annual sales in the billions of dollars, with peak sales estimates ranging from US$2.5 billion to US$14.5 billion per year. Information shows that giredestrant is an oral SERD developed by Roche for the treatment of estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer. Through a "molecular clamp" structure, the therapy fully antagonizes, strongly locks down, and deeply degrades estrogen receptors, blocking the signaling pathway at the source and inhibiting cancer cell growth. Compared with traditional endocrine therapy, its oral administration is more convenient and requires no injections. Phase III research in adjuvant treatment of early breast cancer (lidERA study) showed that, compared with standard endocrine therapy, giredestrant significantly reduced the risk of invasive disease recurrence or death by 30% (HR=0.70), with 3-year invasive disease-free survival rates of 92.4% and 89.6%, respectively. This is the first oral SERD since 2000 to demonstrate superiority over traditional endocrine drugs in adjuvant treatment of early breast cancer. Research in advanced breast cancer treatment (evERA study) showed that giredestrant combined with everolimus achieved a median progression-free survival of 8.77 months in ER+/HER2- advanced patients previously treated with CDK4/6 inhibitors, compared with 5.49 months in the control group; the benefit was even more pronounced in the ESR1-mutant population (9.99 months vs 5.45 months). Roche is preparing for the drug's potential approval and hopes to dominate an entirely new treatment approach for the disease with this drug. Roche is preparing to launch giredestrant in the United States almost immediately after approval, and plans to roll out a companion patient support program to help women start treatment as soon as possible. The U.S. Food and Drug Administration (FDA) has granted priority review to two applications for the drug: one for early breast cancer, with a review decision expected by November 30; the other for advanced breast cancer patients, using the drug in combination with everolimus, a drug that helps slow cancer cell growth, with a review decision expected in December. Currently, oral SERD drugs including Menarini Group's Orserdu and Eli Lilly's (LLY.US) Inluriyo have already been approved for some advanced breast cancer patients, but the eligible patient population is relatively limited. Roche hopes to be first to enter the much larger early breast cancer treatment market and to launch ahead of Astrazeneca PLC Sponsored ADR (AZN.US)'s Etcamah. European patients will need to wait longer to access giredestrant. Roche plans to submit a marketing application for the drug in Europe next year, when more data will be available for inclusion in the application, such as overall survival data. Meanwhile, pricing negotiations could further delay the drug's launch in Europe; if the two sides cannot reach an agreement, the drug may even fail to enter some European markets.